Comparison · NCT00640510-4afa0f7b
IM Olanzapine 10mg vs IM Placebo: Number of Responders at 2 Hours After First Intramuscular (IM) Injection
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IM Olanzapine 10mg vs IM Placebo: Number of Responders at 2 Hours After First Intramuscular (IM) Injection. Trial comparisons, record NCT00640510-4afa0f7b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00640510-4afa0f7b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.188 | 0.0659 | 0.43 | wilson | |
| Risk in group 2 | 0.25 | 0.102 | 0.495 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0625 | -0.336 | 0.222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.199 | 2.83 | log | |
| Odds ratio, group 1 over group 2 | 0.692 | 0.128 | 3.75 | log | |
| Number needed to treat, for one fewer participant with the outcome on IM Olanzapine 10mg than on IM Placebo | 16 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IM Olanzapine 10mg | Patients will receive at least one injection of Intramuscular olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection). | 3 | 16 | OG000 |
| Group 2 | IM Placebo | Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection). | 4 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Responders at 2 Hours After First Intramuscular (IM) Injection
- Description
A responder was defined ast he patient with ≥ 40% decrease in the PANSS-EC total score at 2 hours after the first IM injection in comparison with baseline. (See outcome measure 1 for description of PANSS-EC).
- Time frame
- 2 hours post first IM injection
- Population
- Number of patients having the measures both at baseline and post-baseline. Last Observation Carried Forward.
Source ClinicalTrials.gov
Trial
- Title
- A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia
- NCT number
- NCT00640510
- Phases
- PHASE3
- Conditions
- Schizophrenia
- Interventions
- Rapid Acting Intramuscular Olanzapine, Isotonic sodium chloride solution
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2009-08-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00640510?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00640510-4afa0f7b